<analysis>
**Action 1 (shadow cohort plus novel-channel research).** This has three parts: staffing about 60 shadow episodes, a tractability diagnosis, and a channel-agnostic prototype.
- **Staffing risk.** Four researchers are needed during the next-generation run's evaluation period. The last two times engineers were requested, they were pulled onto the eval harness. A partial clawback is the base case.
- **Prerequisite.** Shadow episodes only yield eval-flag data if the tagging pipeline's ID-join bug is fixed first. That is doable, but it eats the first week or two.
- **Realistic best case.** 20–35 shadow episodes before the late-November decision, a diagnostic memo leaning "partly trainable, partly fundamental," and a rough prototype.
- **Failure mode.** Staff arrive mid-month, a handful of episodes run, and the prototype is a design doc.

**Action 2 (pre-announced release).** Counsel's objection to the 15 November announcement and the DeepMind-sharing question are both modelled in Threat 1, so they are not counted here.
- **Own execution risk.** Three items must land in Thanksgiving week (25 November 2027 is Thursday). That is a slow press week, and analyst initiations fall around the same days.
- **Other risks.** Comms coordination, last-minute securities re-review of the final texts, and DeepMind legal friction over coordination.
- **Base rate.** Four prior slips.

**Action 3 (leadership scenario memo).** This is internal drafting, which is routine. The memo itself is near-certain. Whether leadership adopts the "external validation before scaling" commitment is a separate matter and would be partial at best. Failure here means the memo lands late or has its recommendation shelved.

**Action 4 (direct CISA relationship).** CISA is a third down on staff and faces a 12 December funding cliff. The August attempt failed, and the only link so far is indirect via WaterISAC. Threat 4 models "no meeting," so own-execution risk covers the rest:
- Anthropic policy and legal may refuse to take a public liability-shield position in the first public quarter and during the omnibus.
- The offer may simply be routed to JCDC intake.

**Action 5 (RAISE 5x to 2,000 by 31 December).** This needs new budget, new partners, and onboarding across Thanksgiving and the winter break. Academic calendars make a December target largely infeasible. The likeliest success is an approved expansion with a Q1 target. Threat 5 models the scale-back, so own-execution risk is mainly leadership refusing the funding outright.

**Capability clock and long-static threads.**
- **Gemini 5** release this month: about 65%, resolved in the exogenous events independently of Threat 2's market component. It would lift the frontier to about CI-3.95–4.0.
- **Anthropic's next generation** finishes pretraining around January, with evaluations in February and March. That would be CI-4.1–4.2 by Q1 2028.
- **DeepSeek V5** release this month: about 25%.
- These step changes restore the roughly 0.06/month pace needed for CI-6 by December 2030.

**Threats.**
- **T1.** A forward-looking release statement inside the post-effective window is plausibly treated as a communication. Regulation FD fits poorly, because DeepMind is not a market professional. But the research-review precedent against sharing unreleased-model data is strong.
- **T2.** A single roll for the combined damaging variant (release, a clear overtake, and a sub-offer close). Its components are not independent.
- **T3.** This is conditional on the shadow cohort producing data at all. A high flag rate is plausible given the scale-driven share of eval-awareness.
- **T4.** A single roll for either no direct meeting or negative "immunity" framing.
- **T5.** The academic calendar dominates.
</analysis>

<action_odds>
Action 1 [Shadow cohort + novel-channel research]: P(failure) 50%. Reason: staffing competes with next-generation evaluations, the tagging bug must be fixed first, the scope has three parts, and there are only about three weeks before the decision.

Action 2 [Pre-announced post-effective release]: P(failure) 40%. Reason: three items must be coordinated in Thanksgiving week, final texts need securities re-review, and there are four prior slips. Counsel's objection itself is modelled in Threat 1.

Action 3 [Gate scenario memo]: P(failure) 15%. Reason: routine internal drafting. Adoption of the external-validation commitment is uncertain but does not by itself count as failure.

Action 4 [Direct CISA relationship]: P(failure) 50%. Reason: CISA is at reduced capacity and faces a funding cliff, the August attempt failed, and Anthropic may balk at a public liability-shield position. The no-meeting risk is partly in Threat 4.

Action 5 [RAISE 5x expansion]: P(failure) 55%. Reason: this is new spending in the first public quarter, partners contract slowly, and the holiday calendar makes 2,000 by 31 December nearly infeasible. The scale-back is modelled in Threat 5.
</action_odds>

<threat_odds>
Threat 1 [Counsel strips the 15 Nov commitment]: P(materialises) 50%. Adversary suggested 55%. Reason for the difference: the pattern is strong, but the window closes around 22 November and counsel may allow a bland date-only notice. The Regulation FD angle is weak.

Threat 2 [Gemini 5 overtake + stock below offer]: P(materialises) 40%. Adversary suggested 60% for the release and about 35% for the stock drop. Reason for the difference: this roll covers the combined damaging version. The release alone is about 65% and will be resolved separately.

Threat 3 [Shadow cohort shows high test recognition]: P(materialises) 35%. Adversary suggested 40%. Reason for the difference: it requires the shadow cohort to produce tagged data before the decision, which is itself uncertain. It is plausible given scale-driven awareness.

Threat 4 [Immunity framing / no CISA meeting]: P(materialises) 40%. Adversary suggested 30% for framing and 55% for no meeting. Reason for the difference: a single roll for the combined variant. Part of the no-meeting risk is already in Action 4's P(failure), so it is not double-counted.

Threat 5 [RAISE scaled back / delayed]: P(materialises) 60%. Adversary suggested 65%. Reason for the difference: calendar and cost scrutiny make it likely, but leadership might approve the full target on paper with Q1 delivery.
</threat_odds>
